Eli Lilly (NYSE:LLY) Gains FDA Approval For New Alzheimer's Drug Dosing Schedule

Eli Lilly (NYSE:LLY) recently received FDA approval for a new dosing schedule of Kisunla, aimed at reducing amyloid-related imaging abnormalities in Alzheimer's treatment. This development comes amid a 3% price increase for the company in the last quarter. Despite these gains, market activity remained relatively flat over this period, reflecting industry-wide trends. Liquidity, investor sentiment toward tech giants, and market influences such as revised U.S. trade policy and Nvidia's market cap milestones have weighed on broader market performance. These events, along with Eli Lilly's product and earnings announcements, have added weight to the company's overall market positioning.

We've identified 2 warning signs for Eli Lilly (1 is potentially serious) that you should be aware of.

Find companies with promising cash flow potential yet trading below their fair value.

The recent FDA approval for Eli Lilly's new dosing schedule of Kisunla is expected to enhance its market credibility in Alzheimer's treatment, potentially boosting revenue streams. This aligns with the ongoing expansion in oncology and immunology sectors, underscoring analysts' narratives about Eli Lilly's growth trajectory. The approval may enhance investor confidence, contributing positively to longer-term revenue and earnings forecasts, which already anticipate significant growth.

Over the past five years, Eli Lilly's total shareholder return, including share price gains and dividends, was 403.22%. This reflects a very strong performance compared to its more recent one-year return, which underperformed the US market's 12.6% gain. Within the pharmaceuticals industry, Eli Lilly's performance surpassed the industry's 11.3% decline over the same period.

The current share price is approximately 18.5% below the consensus analyst price target of US$951.98, indicating potential upside from its present value of US$775.9. Given the evolving landscape of product development and approvals, upcoming trials and manufacturing expansions are anticipated to bolster revenue and earnings substantially, although concerns remain about pricing pressures and regulatory impacts.

The valuation report we've compiled suggests that Eli Lilly's current price could be inflated.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com